1. 2012
2. Cyhoeddwyd

   Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group

   Hughes, D., Faulkner, E., Annemans, L., Garrison, L., Helfand, M., Holtorf, A. P., Hornberger, J., Hughes, D. A., Li, T., Malone, D., Payne, K., Siebert, U., Towse, A., Veenstra, D. & Watkins, J., 1 Rhag 2012, Yn: Value in Health. 15, 8, t. 1162-1171

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

3. Cyhoeddwyd

   Cost–effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs

   Hughes, D., Verhof, T. I., Redekop, W. K., van Schie, R. M., Bayat, S., Daly, A. K., Geitona, M., Haschke-Becher, E., Hughes, D. A., Kamali, F., Levin, L. A., Manolopoulos, V. G., Pirmohamed, M., Siebert, U., Stingl, J. C., Wadelius, M., de Boer, A. & Maitland-van der Zee, A. H., 1 Medi 2012, Yn: Pharmacogenomics. 13, 12, t. 1405-1417

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

4. Cyhoeddwyd

   Reimbursement Decisions of the All Wales Medicines Strategy Group

   Hughes, D., Linley, W. G. & Hughes, D. A., 1 Medi 2012, Yn: PharmoEconomics. 30, 9, t. 779-794

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

5. Cyhoeddwyd

   Development of a Database of Instruments for Resource-Use Measurement: Purpose, Feasibility, and Design

   DIRUM Team, 1 Gorff 2012, Yn: Value in Health. 15, 5, t. 650-655

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

6. Cyhoeddwyd

   An agenda for UK clinical pharmacology Pharmacoeconomics

   Hughes, D. & Hughes, D. A., 1 Meh 2012, Yn: British Journal of Clinical Pharmacology. 73, 6, t. 968-972

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

7. Cyhoeddwyd

   A new taxonomy for describing and defining adherence to medications

   Holmes, E. A., Hughes, D., Morrison, V. L., Vrijens, B., De Geest, S., Hughes, D. A., Prezemyslaw, K., Demonceau, J., Ruppar, T., Dobbels, F., Fargher, E., Morrison, V., Lewek, P., Matyjaszczyk, M., Mshelia, C., Clyne, W., Aronson, J. K. & Urquhart, J., 1 Mai 2012, Yn: British Journal of Clinical Pharmacology. 73, 5, t. 691-705

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

8. Cyhoeddwyd

   The development of a QALY measure for epilepsy: NEWQOL-6D

   Hughes, D., Mulhern, B., Rowen, D., Jacoby, A., Marson, T., Snape, D., Hughes, D. A., Latimer, N., Baker, G. A. & Brazier, J. E., 1 Mai 2012, Yn: Epilepsy and Behavior. 24, 1, t. 36-43

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

9. Cyhoeddwyd

   An explanatory randomised controlled trial of a nurse-led, consultation-based intervention to support patients with adherence to taking glucose lowering medication for type 2 diabetes

   Hughes, D., Farmer, A., Hardeman, W., Hughes, D. A., Prevost, A. T., Kim, Y., Craven, A., Oke, J., Boase, S., Selwood, M., Kellar, I., Graffy, J., Griffin, S., Sutton, S. & Kinmonth, A. L., 5 Ebr 2012, Yn: BMC Family Practice. 13, 30

   Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

10. Cyhoeddwyd

    Defining rewardable innovation in drug therapy

    Hughes, D., Aronson, J. K., Ferner, R. E. & Hughes, D. A., 1 Ebr 2012, Yn: Nature Reviews Drug Discovery. 11, t. 253-254

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid

11. Cyhoeddwyd

    A Risk–Benefit Assessment of Prasugrel, Clopidogrel, and Genotype-Guided Therapy in Patients Undergoing Percutaneous Coronary Intervention

    Hughes, D., Guzauskas, G. F., Hughes, D. A., Bradley, S. M. & Veenstra, D. L., 28 Maw 2012, Yn: Clinical Pharmacology and Therapeutics.

    Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl › adolygiad gan gymheiriaid